Protective effects of lupeol in rats with renal ischemia‑reperfusion injury

Kapisiz,Alparslan; Kaya,Cem; Eryilmaz,Sibel; Karabulut,Ramazan; Turkyilmaz,Zafer; Inan,Mehmet Arda; Gulbahar,Ozlem; Sonmez,Kaan

doi:10.3892/etm.2024.12602

Protective effects of lupeol in rats with renal ischemia‑reperfusion injury

Authors:
- Alparslan Kapisiz
- Cem Kaya
- Sibel Eryilmaz
- Ramazan Karabulut
- Zafer Turkyilmaz
- Mehmet Arda Inan
- Ozlem Gulbahar
- Kaan Sonmez
View Affiliations

Affiliations: Department of Pediatric Surgery, Gazi University Faculty of Medicine, Yenimahalle, 06500 Ankara, Turkey, Department of Pathology, Gazi University Faculty of Medicine, Yenimahalle, 06500 Ankara, Turkey, Department of Biochemistry, Gazi University Faculty of Medicine, Yenimahalle, 06500 Ankara, Turkey
Published online on: June 7, 2024 https://doi.org/10.3892/etm.2024.12602
Article Number: 313
Copyright: © Kapisiz et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Acute kidney injury (AKI) caused by ischemia and, exogenous or endogenous nephrotoxic agents poses a serious health issue. AKI is seen in 1% of all hospital admissions, 2‑5% of hospitalizations and 67% of intensive care unit (ICU) patients. The in‑hospital mortality rates for AKI is 40‑50, and >50% for ICU patients. Ischemia‑reperfusion (I/R) injury in the kidney can activate inflammatory responses and oxidative stress, resulting in AKI. The common endpoint in acute tubular necrosis is a cellular insult secondary to ischemia or direct toxins, which results in effacement of brush border, cell death and decreased function of tubular cells. The aim of the present study was to assess if the reported antioxidant and anti‑inflammatory agent lupeol can exert any effects against renal I/R damage. In total, 24 Wistar Albino rats were randomly assigned into four groups of 6, namely Sham, lupeol, ischemia and therapy groups. In the lupeol group, intraperitoneal administration of 100 mg/kg lupeol was given 1 h before laparotomy, whilst only laparotomy was conducted in the sham group. The renal arteries of both kidneys were clamped for 45 min, 1 h after either intraperitoneal saline injection (in the ischemia group) or 100 mg/kg lupeol application (in the therapy group). The blood samples and renal tissues of all rats were collected after 24 h. In blood samples, blood urea nitrogen (BUN) was measured by the urease enzymatic method, and creatinine was measured by the kinetic Jaffe method. Using ELISA method, TNF‑α and IL‑6 levels were measured in the blood samples, whereas malondialdehyde (MDA), glutathione (GSH), caspase‑3 levels were measured in kidney tissues. In addition, kidney histopathological analysis was performed by evaluating the degree of degeneration, tubular dilatation, interstitial lymphocyte infiltration, protein cylinders, necrosis and loss of brush borders. It was determined that renal damage occurred due to higher BUN, creatinine, MDA, TNF‑α and caspase‑3 values observed in the kidney tissues and blood samples of rats in ischemia group compared with the Sham group. Compared with those in the ischemia group, rats in the therapy group exhibited increased levels of GSH and reduced levels of BUN, TNF‑α, MDA. Furthermore, the ischemia group also had reduced histopathological damage scores. Although differences in creatinine, IL‑6 and caspase‑3 levels were not statistically significant, they were markedly reduced in the treatment group. Taken together, these findings suggest that lupeol can prevent kidney damage as mainly evidenced by the reduced histopathological damage scores, decreased levels of oxidative stress and reduced levels of inflammatory markers. These properties may allow lupeol to be used in the treatment of AKI.

View Figures

View References

1	Ronco C, Bellomo R and Kellum JA: Acute kidney injury. Lancet. 394:1949–1964. 2019.PubMed/NCBI View Article : Google Scholar
2	Shaikhouni S and Yessayan L: Management of acute kidney injury/renal replacement therapy in the intensive care unit. Surg Clin North Am. 102:181–198. 2022.PubMed/NCBI View Article : Google Scholar
3	Thapa K, Singh TG and Kaur A: Targeting ferroptosis in ischemia/reperfusion renal injury. Naunyn Schmiedebergs Arch Pharmacol. 395:1331–1341. 2022.PubMed/NCBI View Article : Google Scholar
4	Kaya C, Karabulut R, Turkyilmaz Z, Sonmez K, Kulduk G, Gülbahar Ö, Köse F and Basaklar AC: Lycopene has reduced renal damage histopathologically and biochemically in experimental renal ischemia-reperfusion injury. Ren Fail. 37:1390–1395. 2015.PubMed/NCBI View Article : Google Scholar
5	Kinra M, Mudgal J, Arora D and Nampoothiri M: An insight into the role of cyclooxygenase and lipooxygenase pathway in renal ischemia. Eur Rev Med Pharmacol Sci. 21:5017–5020. 2017.PubMed/NCBI
6	Miao AF, Liang JX, Yao L, Han JL and Zhou LJ: Hypoxia-inducible factor prolyl hydroxylase inhibitor roxadustat (FG-4592) protects against renal ischemia/reperfusion injury by inhibiting inflammation. Ren Fail. 43:803–810. 2021.PubMed/NCBI View Article : Google Scholar
7	Katagiri D, Wang F, Gore JC, Harris RC and Takahashi T: Clinical and experimental approaches for imaging of acute kidney injury. Clin Exp Nephrol. 25:685–699. 2021.PubMed/NCBI View Article : Google Scholar
8	Tao Q, Zhang Q, An Z, Chen Z and Feng Y: Multi-Parametric MRI for evaluating variations in renal structure, function, and endogenous metabolites in an animal model with acute kidney injury induced by ischemia reperfusion. J Magn Reson Imaging: Oct 26, 2023 (Epub ahead of print).
9	Bonventre JV and Yang L: Cellular pathophysiology of ischemic acute kidney injury. J Clin Invest. 121:4210–4221. 2011.PubMed/NCBI View Article : Google Scholar
10	Wu MY, Yiang GT, Liao WT, Tsai AP, Cheng YL, Cheng PW, Li CY and Li CJ: Current mechanistic concepts in ischemia and reperfusion injury. Cell Physiol Biochem. 46:1650–1667. 2018.PubMed/NCBI View Article : Google Scholar
11	Nath KA and Norby SM: Reactive oxygen species and acute renal failure. Am J Med. 109:665–678. 2000.PubMed/NCBI View Article : Google Scholar
12	Zhu H, Tan Y, Du W, Li Y, Toan S, Mui D, Tian F and Zhou H: Phosphoglycerate mutase 5 exacerbates cardiac ischemia-reperfusion injury through disrupting mitochondrial quality control. Redox Biol. 38(101777)2021.PubMed/NCBI View Article : Google Scholar
13	Malek M and Nematbakhsh M: Renal ischemia/reperfusion injury; from pathophysiology to treatment. J Renal Inj Prev. 4:20–27. 2015.PubMed/NCBI View Article : Google Scholar
14	Lin Y, Xu L, Lin H, Cui W, Jiao Y, Wang B, Li H, Wang X and Wu J: Network pharmacology and experimental validation to investigate the mechanism of Nao-Ling-Su capsule in the treatment of ischemia/reperfusion-induced acute kidney injury. J Ethnopharmacol. 326(117958)2024.PubMed/NCBI View Article : Google Scholar
15	Ruiz-Rodríguez MA, Vedani A, Flores-Mireles AL, Cháirez-Ramírez MH, Gallegos-Infante JA and González-Laredo RF: In Silico prediction of the toxic potential of lupeol. Chem Res Toxicol. 30:1562–1571. 2017.PubMed/NCBI View Article : Google Scholar
16	Liu K, Zhang X, Xie L, Deng M, Chen H, Song J, Long J, Li X and Luo J: Lupeol and its derivatives as anticancer and anti-inflammatory agents: Molecular mechanisms and therapeutic efficacy. Pharmacol Res. 164(105373)2021.PubMed/NCBI View Article : Google Scholar
17	Sohag AAM, Hossain MT, Rahaman MA, Rahman P, Hasan MS, Das RC, Khan MK, Sikder MH, Alam M, Uddin MJ, et al: Molecular pharmacology and therapeutic advances of the pentacyclic triterpene lupeol. Phytomedicine. 99(154012)2022.PubMed/NCBI View Article : Google Scholar
18	Park JS, Rehman IU, Choe K, Ahmad R, Lee HJ and Kim MO: A triterpenoid lupeol as an antioxidant and anti-neuroinflammatory agent: Impacts on oxidative stress in Alzheimer's disease. Nutrients. 15(3059)2023.PubMed/NCBI View Article : Google Scholar
19	Schloss J, Ryan K, Reid R and Steel A: A randomised, double-blind, placebo-controlled clinical trial assessing the efficacy of bedtime buddy® for the treatment of nocturnal enuresis in children. BMC Pediatr. 19(421)2019.PubMed/NCBI View Article : Google Scholar
20	Sudhahar V, Ashok Kumar S, Varalakshmi P and Sujatha V: Protective effect of lupeol and lupeol linoleate in hypercholesterolemia associated renal damage. Mol Cell Biochem. 317:11–20. 2008.PubMed/NCBI View Article : Google Scholar
21	Nitta M, Azuma K, Hata K, Takahashi S, Ogiwara K, Tsuka T, Imagawa T, Yokoe I, Osaki T, Minami S and Okamoto Y: Systemic and local injections of lupeol inhibit tumor growth in a melanoma-bearing mouse model. Biomed Rep. 1:641–645. 2013.PubMed/NCBI View Article : Google Scholar
22	Sunitha S, Nagaraj M and Varalakshmi P: Hepatoprotective effect of lupeol and lupeol linoleate on tissue antioxidant defence system in cadmium-induced hepatotoxicity in rats. Fitoterapia. 72:516–523. 2001.PubMed/NCBI View Article : Google Scholar
23	Murtaza I, Saleem M, Adhami VM, Hafeez BB and Mukhtar H: Suppression of cFLIP by lupeol, a dietary triterpene, is sufficient to overcome resistance to TRAIL-mediated apoptosis in chemoresistant human pancreatic cancer cells. Cancer Res. 69:1156–1165. 2009.PubMed/NCBI View Article : Google Scholar
24	Saleem M, Afaq F, Adhami VM and Mukhtar H: Lupeol modulates NF-kappaB and PI3K/Akt pathways and inhibits skin cancer in CD-1 mice. Oncogene. 23:5203–5214. 2004.PubMed/NCBI View Article : Google Scholar
25	Siddique HR and Saleem M: Beneficial health effects of lupeol triterpene: A review of preclinical studies. Life Sci. 88:285–293. 2011.PubMed/NCBI View Article : Google Scholar
26	Ahmad SF, Pandey A, Kour K and Bani S: Downregulation of pro-inflammatory cytokines by lupeol measured using cytometric bead array immunoassay. Phytother Res. 24:9–13. 2010.PubMed/NCBI View Article : Google Scholar
27	Al-Mousawi AM, Kulp GA, Branski LK, Kraft R, Mecott GA, Williams FN, Herndon DN and Jeschke MG: Impact of anesthesia, analgesia, and euthanasia technique on the inflammatory cytokine profile in a rodent model of severe burn injury. Shock. 34:261–268. 2010.PubMed/NCBI View Article : Google Scholar
28	Rampil IJ and Laster MJ: No correlation between quantitative electroencephalographic measurements and movement response to noxious stimuli during isoflurane anesthesia in rats. Anesthesiology. 77:920–925. 1992.PubMed/NCBI View Article : Google Scholar
29	Kumari A and Kakkar P: Lupeol protects against acetaminophen-induced oxidative stress and cell death in rat primary hepatocytes. Food Chem Toxicol. 50:1781–1789. 2012.PubMed/NCBI View Article : Google Scholar
30	Liu H, Wang L, Weng X, Chen H, Du Y, Diao C, Chen Z and Liu X: Inhibition of Brd4 alleviates renal ischemia/reperfusion injury-induced apoptosis and endoplasmic reticulum stress by blocking FoxO4-mediated oxidative stress. Redox Biol. 24(101195)2019.PubMed/NCBI View Article : Google Scholar
31	Zheng Y, Zhang N and Bai F: Gastrodin pretreatment alleviates renal ischemia-reperfusion injury. Urol Int. 106:630–637. 2022.PubMed/NCBI View Article : Google Scholar
32	Feng W, Remedies CE, Obi IE, Aldous SR, Meera SI, Sanders PW, Inscho EW and Guan Z: Restoration of afferent arteriolar autoregulatory behavior in ischemia-reperfusion injury in rat kidneys. Am J Physiol Renal Physiol. 320:F429–F441. 2021.PubMed/NCBI View Article : Google Scholar
33	Williams P, Lopez H, Britt D, Chan C, Ezrin A and Hottendorf R: Characterization of renal ischemia-reperfusion injury in rats. J Pharmacol Toxicol Methods. 37:1–7. 1997.PubMed/NCBI View Article : Google Scholar
34	Chatterjee PK: Novel pharmacological approaches to the treatment of renal ischemia-reperfusion injury: A comprehensive review. Naunyn Schmiedebergs Arch Pharmacol. 376:1–43. 2007.PubMed/NCBI View Article : Google Scholar
35	Eryilmaz S, Turkyilmaz Z, Karabulut R, Gulburun MA, Poyraz A, Gulbahar O, Arslan B and Sonmez K: The effects of hydrogen-rich saline solution on intestinal anastomosis performed after intestinal ischemia reperfusion injury. J Pediatr Surg. 55:1574–1578. 2020.PubMed/NCBI View Article : Google Scholar
36	Shan Y, Chen D, Hu B, Xu G, Li W, Jin Y, Jin X, Jin X and Jin L: Allicin ameliorates renal ischemia/reperfusion injury via inhibition of oxidative stress and inflammation in rats. Biomed Pharmacother. 142(112077)2021.PubMed/NCBI View Article : Google Scholar
37	Zhang Y, Liu M, Zhang Y, Tian M, Chen P, Lan Y and Zhou B: Urolithin A alleviates acute kidney injury induced by renal ischemia reperfusion through the p62-Keap1-Nrf2 signaling pathway. Phytother Res. 36:984–995. 2022.PubMed/NCBI View Article : Google Scholar
38	Wang Q, Ju F, Li J, Liu T, Zuo Y, Abbott GW and Hu Z: Empagliflozin protects against renal ischemia/reperfusion injury in mice. Sci Rep. 12(19323)2022.PubMed/NCBI View Article : Google Scholar
39	Tang S, Xie X, Wang M, Yang L and Wei W: Protective effects of asiaticoside on renal ischemia reperfusion injury in vivo and in vitro. Bioengineered. 13:10235–10243. 2022.PubMed/NCBI View Article : Google Scholar
40	Nezamoleslami S, Sheibani M, Jahanshahi F, Mumtaz F, Abbasi A and Dehpour AR: Protective effect of dapsone against renal ischemia-reperfusion injury in rat. Immunopharmacol Immunotoxicol. 42:272–279. 2020.PubMed/NCBI View Article : Google Scholar
41	Beserra FP, Vieira AJ, Gushiken LFS, de Souza EO, Hussni MF, Hussni CA, Nóbrega RH, Martinez ERM, Jackson CJ, de Azevedo Maia GL, et al: Lupeol, a dietary triterpene, enhances wound healing in streptozotocin-induced hyperglycemic rats with modulatory effects on inflammation, oxidative stress, and angiogenesis. Oxid Med Cell Longev. 2019(3182627)2019.PubMed/NCBI View Article : Google Scholar
42	Preetha SP, Kanniappan M, Selvakumar E, Nagaraj M and Varalakshmi P: Lupeol ameliorates aflatoxin B1-induced peroxidative hepatic damage in rats. Comp Biochem Physiol C Toxicol Pharmacol. 143:333–339. 2006.PubMed/NCBI View Article : Google Scholar
43	Zhang Z, Xu C, Hao J, Zhang M, Wang Z, Yin T, Lin K, Liu W, Jiang Q, Li Z, et al: Beneficial consequences of Lupeol on middle cerebral artery-induced cerebral ischemia in the rat involves Nrf2 and P38 MAPK modulation. Metab Brain Dis. 35:841–848. 2020.PubMed/NCBI View Article : Google Scholar
44	Asha R, Gayathri Devi V and Abraham A: Lupeol, a pentacyclic triterpenoid isolated from Vernonia cinerea attenuate selenite induced cataract formation in Sprague Dawley rat pups. Chem Biol Interact. 245:20–29. 2016.PubMed/NCBI View Article : Google Scholar
45	Li J, Ma X, Yang J, Wang L, Huang Y and Zhu Y: Lupeol alleviates myocardial ischemia-reperfusion injury in rats by regulating NF-[Formula: See text]B and Nrf2 pathways. Am J Chin Med. 50:1269–1280. 2022.PubMed/NCBI View Article : Google Scholar
46	Srivastava AK, Mishra S, Ali W and Shukla Y: Protective effects of lupeol against mancozeb-induced genotoxicity in cultured human lymphocytes. Phytomedicine. 23:714–724. 2016.PubMed/NCBI View Article : Google Scholar
47	Kim MJ, Bae GS, Choi SB, Jo IJ, Kim DG, Shin JY, Lee SK, Kim MJ, Song HJ and Park SJ: Lupeol protects against cerulein-induced acute pancreatitis in mice. Phytother Res. 29:1634–1639. 2015.PubMed/NCBI View Article : Google Scholar
48	Ni J, Jiang L, Shen G, Xia Z, Zhang L, Xu J, Feng Q, Qu H, Xu F and Li X: Hydrogen sulfide reduces pyroptosis and alleviates ischemia-reperfusion-induced acute kidney injury by inhibiting NLRP3 inflammasome. Life Sci. 284(119466)2021.PubMed/NCBI View Article : Google Scholar
49	Zhang B, Wan S, Liu H, Qiu Q, Chen H, Chen Z, Wang L and Liu X: Naringenin alleviates renal ischemia reperfusion injury by suppressing ER stress-induced pyroptosis and apoptosis through activating Nrf2/HO-1 signaling pathway. Oxid Med Cell Longev. 2022(5992436)2022.PubMed/NCBI View Article : Google Scholar
50	Wang Z, Han Y, Tian S, Bao J, Wang Y and Jiao J: Lupeol alleviates cerebral ischemia-reperfusion injury in correlation with modulation of PI3K/Akt pathway. Neuropsychiatr Dis Treat. 16:1381–1390. 2020.PubMed/NCBI View Article : Google Scholar
51	Karimi G, Ramezani M and Tahoonian Z: Cisplatin nephrotoxicity and protection by milk thistle extract in rats. Evid Based Complement Alternat Med. 2:383–386. 2005.PubMed/NCBI View Article : Google Scholar
52	Yokoe I, Azuma K, Hata K, Mukaiyama T, Goto T, Tsuka T, Imagawa T, Itoh N, Murahata Y, Osaki T, et al: Clinical systemic lupeol administration for canine oral malignant melanoma. Mol Clin Oncol. 3:89–92. 2015.PubMed/NCBI View Article : Google Scholar
53	Jesus JA, da Silva TNF, Sousa IMO, Ferreira AF, Laurenti MD, da Costa PC, de Carvalho Ferreira D and Passero LFD: Nanostructured lipid carriers as robust systems for lupeol delivery in the treatment of experimental visceral leishmaniasis. Pharmaceuticals (Basel). 16(1646)2023.PubMed/NCBI View Article : Google Scholar
54	Cháirez-Ramírez MH, Gallegos-Infante JA, Moreno-Jiménez MR, González-Laredo RF and Rocha-Guzmán NE: Absorption and distribution of lupeol in CD-1 mice evaluated by UPLC-APCI⁺ -MS/MS. Biomed Chromatogr. 33(e4432)2019.PubMed/NCBI View Article : Google Scholar
55	Yang X, Feng Y, Liu Y, Ye X, Ji X, Sun L, Gao F, Zhang Q, Li Y, Zhu B and Wang X: Fuzheng Jiedu Xiaoji formulation inhibits hepatocellular carcinoma progression in patients by targeting the AKT/CyclinD1/p21/p27 pathway. Phytomedicine. 87(153575)2021.PubMed/NCBI View Article : Google Scholar